Does a SOX10 Positive Result Mean Cancer?

A SOX10-positive result on a pathology report does not, by itself, mean cancer. SOX10 is a protein that normally appears in several cell types throughout the body, including the pigment-producing cells in your skin and the supporting cells around your nerves. Pathologists use it as one piece of a larger diagnostic puzzle, and it lights up in both benign and malignant tissue. Understanding what SOX10 positivity actually tells your medical team requires knowing where and why the stain was ordered, what other markers were tested alongside it, and what the cells look like under the microscope.

What SOX10 Is and Why Pathologists Look for It

SOX10 is a transcription factor, a protein that helps switch certain genes on or off during development. It plays a critical role in the growth and survival of cells that originate from something called the neural crest, a group of embryonic cells that eventually become melanocytes (the cells that give skin its pigment), Schwann cells (which insulate nerves), and several other specialized cell types. Because SOX10 stays active in these cells throughout life, pathologists can use an antibody stain to detect it in tissue samples. When SOX10 shows up, it tells the pathologist the tissue likely comes from one of those neural crest lineages.

The staining process itself is straightforward. A thin slice of tissue, usually preserved in a wax block, is treated with an antibody that binds to SOX10 protein in the cell nucleus. A chemical reaction then makes those nuclei visible under the microscope, typically as a colored signal against an otherwise pale background.¹ This technique, called immunohistochemistry, is one of the most widely used tools in surgical pathology. SOX10 is just one stain in a panel of many that pathologists choose from depending on what kind of tumor they suspect.

Normal Tissues That Are SOX10 Positive

One of the most important reasons a SOX10-positive result does not equal cancer is that plenty of healthy, non-cancerous cells express this protein. Every melanocyte in normal skin is SOX10-positive, and so are benign moles. A study examining a range of tissue types found that all 43 benign nevi, all 18 dysplastic nevi, all 68 non-cancerous skin samples tested, and all 56 samples of non-cancerous breast tissue were SOX10-positive.² In breast tissue specifically, SOX10 appears in both the myoepithelial cells that surround the milk ducts and in some of the lining cells, with patchy and variable intensity.³

Schwann cells, the cells that wrap around peripheral nerves to form their protective insulation, are also SOX10-positive in their normal state. So are sustentacular cells, the supportive glial-like cells found in structures like the adrenal gland and certain nerve clusters.⁴ In short, SOX10 is a marker of cell lineage, not a marker of malignancy. It tells the pathologist what kind of cell they are looking at, not whether that cell is cancerous.

Where SOX10 Is Most Useful in Cancer Diagnosis

If SOX10 cannot tell benign from malignant on its own, you might wonder why pathologists bother ordering it. The answer is that SOX10’s real value lies in confirming what kind of cancer is present once other evidence already points toward malignancy. In specific clinical scenarios, it is one of the most reliable stains available.

Melanoma

SOX10’s strongest and best-studied role is in melanoma diagnosis. When a pathologist suspects that a tumor in a lymph node or a distant organ might be metastatic melanoma, SOX10 is among the first stains they reach for. In one study of sentinel lymph nodes, SOX10 identified metastatic melanoma in all 58 confirmed positive cases, and it stained a significantly higher percentage of tumor cells with greater intensity than the older markers S100, HMB-45, and Melan-A.⁵ A larger study found that about 93% of melanomas were positive for both SOX10 and S100, while roughly 4% were negative for both markers entirely.⁶

SOX10 has a practical advantage in lymph node evaluation. S100 protein, the traditional go-to melanoma marker, also stains dendritic immune cells that are normally scattered throughout lymph nodes, making it tricky to distinguish a few melanoma cells from background immune activity. SOX10 avoids this problem because those immune cells do not express it, giving the pathologist a cleaner signal.⁶ SOX10 is also helpful with heavily pigmented tumors, such as uveal melanoma in the eye, where the dark pigment can obscure cytoplasmic stains. Because SOX10 produces a nuclear signal instead, it is easier to read even against a heavily pigmented background.⁷

Nerve Sheath Tumors

Tumors arising from Schwann cells and related nerve sheath elements are another major area where SOX10 is diagnostically valuable. Benign schwannomas, neurofibromas, and their malignant counterpart, malignant peripheral nerve sheath tumors (MPNSTs), all relate to the same cell lineage. Interestingly, SOX10 behaves differently in benign versus malignant nerve sheath tumors. Benign schwannomas retain strong, uniform SOX10 expression, whereas MPNSTs frequently lose it. In one study, complete loss of SOX10 expression was actually specific for MPNST rather than for a benign schwannoma.⁸ So in the nerve sheath tumor world, loss of SOX10 can be a warning sign, the opposite of what people often assume about positive-equals-bad.

Salivary Gland Tumors

SOX10 has carved out an especially useful niche in salivary gland pathology, where several tumor types can look confusingly similar under the microscope. SOX10 helps sort them into two camps. Tumors that arise from the acinar and intercalated duct cells of the salivary gland, including adenoid cystic carcinoma, acinic cell carcinoma, epithelial-myoepithelial carcinoma, and pleomorphic adenoma, tend to be SOX10-positive. Tumors from a different lineage, such as salivary duct carcinoma, mucoepidermoid carcinoma, and Warthin tumor, are typically SOX10-negative.⁹ Importantly, some of these SOX10-positive salivary gland tumors are benign (like pleomorphic adenoma), reinforcing the point that a positive result does not automatically indicate malignancy.¹⁰

All adenoid cystic carcinomas, whether they originated in the salivary gland, the breast, or elsewhere, show strong and diffuse SOX10 staining, making it a useful marker when pathologists are trying to confirm this specific diagnosis.¹¹

SOX10 in Breast Cancer

SOX10’s role in breast pathology deserves its own discussion because the picture is more nuanced than it is in melanoma. Normal breast tissue, as mentioned earlier, is SOX10-positive in its myoepithelial cells. Among breast cancers, SOX10 positivity clusters heavily in specific subtypes. Triple-negative breast cancers, which lack the three receptors (estrogen, progesterone, and HER2) that other breast cancers use for targeted treatment, show SOX10 positivity at notably high rates. One study of 150 triple-negative cases found SOX10 staining in about 78% of primary tumors and a nearly identical rate in their metastases, with very high concordance between the two.¹² Another study of 113 triple-negative breast cancers found SOX10 positivity in about 41% of cases, with positive tumors tending to be smaller at diagnosis.¹³

This makes SOX10 particularly useful in one common diagnostic dilemma: when a pathologist encounters a metastatic tumor that could be either a squamous cell carcinoma from the lung, cervix, or esophagus, or a metaplastic squamous breast cancer. In one series, 45% of metaplastic squamous cell carcinomas of the breast were SOX10-positive, while SOX10 was entirely negative in over 200 squamous carcinomas from non-breast sites.¹² When a squamous-looking cancer in a lymph node stains positive for SOX10, the breast becomes a much more likely origin.

When SOX10 Shows Up in Unexpected Places

One of the challenges with any immunohistochemical marker is that no stain is perfectly specific. SOX10 is no exception. A large systematic analysis of over 5,000 tumors found that while SOX10 was overwhelmingly associated with melanocytic and nerve sheath tumors, it also appeared in some carcinomas, including about 6% of head and neck squamous cell carcinomas and 7% of small cell lung carcinomas. SOX10 was also expressed in soft tissue myoepithelial tumors and occasionally in embryonal carcinoma.¹⁴ These numbers are small, but they matter when a patient has a tumor of unknown origin. A SOX10-positive result in an unexpected context does not automatically mean melanoma; the pathologist has to weigh it against cell morphology, clinical history, and other stains.

SOX10 also detects sustentacular cells in paragangliomas, a type of neuroendocrine tumor. About 85% of paragangliomas showed SOX10-positive sustentacular cells in one study, compared with only 7% of other neuroendocrine tumors, making it a useful distinguishing marker between these categories.¹⁵ Paragangliomas, it is worth noting, are often benign, with only a subset behaving aggressively. So SOX10 positivity in a paraganglioma does not signal malignancy either.

Why Pathologists Never Rely on a Single Stain

If you are reading your own pathology report and see “SOX10 positive,” the single most important thing to understand is that pathologists interpret these markers in panels, never in isolation. A typical workup for a melanocytic lesion might include SOX10 alongside S100, HMB-45, and Melan-A. All four of these stains have different strengths. SOX10 and Melan-A stain a comparable number of melanocytes in benign lesions and perform similarly in sensitivity, while HMB-45 stains fewer cells overall.¹⁶ But HMB-45 has a useful quirk: it tends to stain more strongly in the superficial part of a mole and fade deeper, which can help distinguish a benign mole from melanoma in ambiguous cases. Each stain compensates for the others’ blind spots.

For tumors of uncertain origin, SOX10 can be paired with keratin markers in a dual-color stain. If a tumor cell is SOX10-positive and keratin-negative, it is likely melanocytic or neural. If it is keratin-positive and SOX10-negative, it is likely a carcinoma. And if it shows both, that narrows the possibilities to a small group of tumors, such as triple-negative breast cancer, that co-express both.¹⁷ The pattern of multiple markers together is what guides the diagnosis, not any single one.

SOX10 as More Than a Diagnostic Tag

Beyond its role as a stain pathologists use to identify tumors, SOX10 is an active player in how certain cancers behave, particularly melanoma. Research has shown that when SOX10 is experimentally silenced in melanoma cells, those cells lose much of their ability to invade surrounding tissue and, over time, also stop proliferating and begin to die. SOX10 appears to drive invasion partly by regulating a protein called MIA (melanoma inhibitory activity).¹⁸ It also activates the MITF pathway, which governs melanoma cell survival, proliferation, and the ability to form metastases.¹⁹

The relationship between SOX10 and drug resistance in melanoma adds another layer of complexity. Melanoma cells that lose SOX10 expression tend to become slower-growing but more invasive, and they tolerate targeted therapies like BRAF and MEK inhibitors better than SOX10-expressing cells. This SOX10-low state appears to be a kind of survival mode that melanoma cells shift into when exposed to drugs, potentially acting as a stepping stone toward full-blown drug resistance. Researchers have identified a class of drugs (cIAP1/2 inhibitors) that selectively kill these SOX10-deficient cells, and combining them with standard targeted therapy delayed resistance in animal models.²⁰ This is still early-stage research, but it suggests that SOX10’s presence or absence in melanoma cells is not just a diagnostic footnote. It reflects something meaningful about the tumor’s biology and its likely response to treatment.

SOX10 Outside of Cancer Entirely

SOX10 is not exclusively a cancer-related protein. Its role in normal development is so fundamental that mutations in the SOX10 gene itself cause a rare genetic condition called Waardenburg-Hirschsprung disease, which combines hearing loss and pigmentation abnormalities (from defective melanocyte development) with a severe intestinal motility disorder (from defective nerve cell development in the gut). Patients with this condition carry mutations that essentially leave them with only half the normal amount of functional SOX10 protein.²¹ The fact that losing just one working copy of SOX10 causes such dramatic developmental problems underscores how central this protein is to normal biology, far beyond any connection to cancer.

If your pathology report mentions SOX10, the context surrounding it matters far more than the positive or negative result alone. A SOX10-positive benign mole, a SOX10-positive schwannoma, and a SOX10-positive metastatic melanoma are three vastly different clinical situations, even though they share the same staining result. Your pathologist considers the cell morphology, the clinical scenario, and the full panel of stains before arriving at a diagnosis. The SOX10 result is one input into that process, an informative one, but never the final word on its own.

1
PubMed Central. Diagnostic value of SOX-10 immunohistochemical staining for the detection of uveal melanoma
2
PubMed. SOX10 expression in malignant melanoma, carcinoma, and normal tissues
3
PubMed. SOX10 expression in mammary invasive ductal carcinomas and benign breast tissue
4
PubMed Central. Postnatal sustentacular cells as chromaffin progenitors and tumor cells of origin in VHL-related paragangliomas
5
Applied Immunohistochemistry and Molecular Morphology. SOX10: A useful marker for identifying metastatic melanoma in sentinel lymph nodes
6
PubMed. SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment
7
ecancermedicalscience. Diagnostic value of SOX-10 immunohistochemical staining for the detection of uveal melanoma
8
PubMed Central. Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas
9
PubMed. SOX10 is a novel marker of acinus and intercalated duct differentiation in salivary gland tumors: a clue to the histogenesis for tumor diagnosis
10
PubMed. SOX10-positive salivary gland tumors: a growing list, including mammary analogue secretory carcinoma of the salivary gland, sialoblastoma, low-grade salivary duct carcinoma, basal cell adenoma/adenocarcinoma, and a subgroup of mucoepidermoid carcinoma
11
PubMed Central. SOX10 Is a Sensitive Marker for Breast and Salivary Gland Adenoid Cystic Carcinoma: Immunohistochemical Characterization of Adenoid Cystic Carcinomas
12
PubMed Central. SOX10 – A Novel Marker for the Differential Diagnosis of Breast Metaplastic Squamous Cell Carcinoma
13
PubMed Central. Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples
14
American Journal of Surgical Pathology. Sox10 – A marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: A systematic analysis of 5134 tumors
15
PubMed Central. Immunohistochemical distinction of paragangliomas from epithelial neuroendocrine tumors-gangliocytic duodenal and cauda equina paragangliomas align with epithelial neuroendocrine tumors
16
PubMed Central. Comparison of SOX-10, HMB-45, and Melan-A in Benign Melanocytic Lesions
17
PubMed. SOX10/keratin dual-color immunohistochemistry: An effective first-line test for the workup of epithelioid malignant neoplasms in FNA and small biopsy specimens
18
PubMed. SOX10 promotes melanoma cell invasion by regulating melanoma inhibitory activity
19
PubMed Central. SOX10-MITF pathway activity in melanoma cells
20
Nature Communications. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma
21
PubMed. SOX10 mutations in patients with Waardenburg-Hirschsprung disease